Equities Research Analysts’ Price Target Changes for November 19th (ADRX, AMRZ, AXGN, BAK, BMO, BNS, BNTX, BRBR, CM, CRR.UN)

Equities Research Analysts’ price target changes for Thursday, November 19th:

ADARx Pharmaceuticals (NASDAQ:ADRX) had its target price trimmed by JPMorgan Chase & Co. from $38.00 to $36.00. The firm currently has an overweight rating on the stock.

Amrize (NYSE:AMRZ) had its price target reduced by JPMorgan Chase & Co. from $48.00 to $46.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.

AxoGen (NASDAQ:AXGN) had its price target raised by Leerink Partners from $56.00 to $65.00. Leerink Partners currently has an outperform rating on the stock.

Braskem (NYSE:BAK) had its price target reduced by UBS Group from $1.50 to $0.75. They currently have a sell rating on the stock.

Bank of Montreal (TSE:BMO) (NYSE:BMO) had its target price increased by Royal Bank Of Canada from C$241.00 to C$258.00. The firm currently has a sector perform rating on the stock.

Bank of Montreal (TSE:BMO) (NYSE:BMO) had its price target increased by Scotiabank from C$270.00 to C$272.00. The firm currently has a sector outperform rating on the stock.

Bank of Nova Scotia (TSE:BNS) (NYSE:BNS) had its target price raised by Royal Bank Of Canada from C$129.00 to C$138.00. They currently have a sector perform rating on the stock.

BioNTech (NASDAQ:BNTX) had its price target increased by JPMorgan Chase & Co. from $92.00 to $93.00. They currently have a neutral rating on the stock.

BellRing Brands (NYSE:BRBR) had its price target boosted by JPMorgan Chase & Co. from $15.00 to $18.00. They currently have an overweight rating on the stock.

BellRing Brands (NYSE:BRBR) had its price target boosted by UBS Group from $9.50 to $15.00. They currently have a neutral rating on the stock.

Canadian Imperial Bank of Commerce (TSE:CM) (NYSE:CM) had its target price raised by Royal Bank Of Canada from C$176.00 to C$177.00. Royal Bank Of Canada currently has an outperform rating on the stock.

Canadian Imperial Bank of Commerce (TSE:CM) (NYSE:CM) had its target price boosted by Scotiabank from C$174.00 to C$175.00. The firm currently has a sector perform rating on the stock.

Crombie Real Estate Investment Trust (TSE:CRR.UN) was given a C$18.00 target price by analysts at TD. The firm currently has a buy rating on the stock.

Crombie Real Estate Investment Trust (TSE:CRR.UN) had its price target reduced by Desjardins from C$19.00 to C$18.50. The firm currently has a buy rating on the stock.

Crombie Real Estate Investment Trust (TSE:CRR.UN) had its target price increased by Raymond James Financial from C$19.00 to C$19.25. The firm currently has an outperform rating on the stock.

Edison International (NYSE:EIX) had its price target increased by JPMorgan Chase & Co. from $59.00 to $64.00. The firm currently has a neutral rating on the stock.

EQB (TSE:EQB) had its price target boosted by Royal Bank Of Canada from C$146.00 to C$147.00. They currently have an outperform rating on the stock.

EQB (TSE:EQB) had its target price boosted by Scotiabank from C$137.00 to C$139.00. The firm currently has a sector perform rating on the stock.

EquipmentShare.com (NASDAQ:EQPT) had its price target lowered by UBS Group from $22.00 to $17.00. They currently have a neutral rating on the stock.

Eagle Materials (NYSE:EXP) had its price target trimmed by JPMorgan Chase & Co. from $200.00 to $190.00. The firm currently has a neutral rating on the stock.

Expeditors International of Washington (NASDAQ:EXPD) had its target price increased by UBS Group from $245.00 to $252.00. UBS Group currently has a buy rating on the stock.

Global-e Online (NASDAQ:GLBE) had its target price lowered by UBS Group from $54.00 to $50.00. The firm currently has a buy rating on the stock.

Gulfport Energy (NYSE:GPOR) had its price target lowered by UBS Group from $217.00 to $210.00. UBS Group currently has a buy rating on the stock.

ITG (NASDAQ:ITG) had its target price lowered by UBS Group from $18.00 to $10.00. They currently have a buy rating on the stock.

JBS (NYSE:JBS) had its price target reduced by UBS Group from $17.00 to $16.50. The firm currently has a buy rating on the stock.

Kodiak Sciences (NASDAQ:KOD) had its target price raised by JPMorgan Chase & Co. from $124.00 to $128.00. The firm currently has an overweight rating on the stock.

Koryx Copper (CVE:KRY) had its target price increased by Stifel Nicolaus from C$4.50 to C$6.00. The firm currently has a buy rating on the stock.

Lowe’s Companies (NYSE:LOW) had its target price cut by UBS Group from $275.00 to $269.00. UBS Group currently has a buy rating on the stock.

MINISO Group (NYSE:MNSO) had its price target trimmed by JPMorgan Chase & Co. from $16.00 to $14.00. They currently have an overweight rating on the stock.

Metro (TSE:MRU) had its target price raised by Scotia from C$96.00 to C$99.00. They currently have a sector perform rating on the stock.

Metro (TSE:MRU) had its target price raised by BMO Capital Markets from C$95.00 to C$108.00. BMO Capital Markets currently has a market perform rating on the stock.

Metro (TSE:MRU) had its target price increased by National Bank Financial from C$102.00 to C$106.00. National Bank Financial currently has a sector perform rating on the stock.

National Bank of Canada (TSE:NA) had its price target boosted by Royal Bank Of Canada from C$224.00 to C$227.00. Royal Bank Of Canada currently has a sector perform rating on the stock.

National Bank of Canada (TSE:NA) had its price target lowered by Scotiabank from C$243.00 to C$234.00. Scotiabank currently has a sector outperform rating on the stock.

Nouveau Monde Graphite (CVE:NOU) had its target price lowered by National Bank Financial from C$3.50 to C$3.00. The firm currently has an outperform rating on the stock.

NexGen Energy (TSE:NXE) had its price target lowered by Royal Bank Of Canada from C$20.00 to C$18.00. They currently have an outperform rating on the stock.

BeOne Medicines (NASDAQ:ONC) had its target price raised by JPMorgan Chase & Co. from $445.00 to $460.00. They currently have an overweight rating on the stock.

Everpure (NYSE:P) had its target price boosted by UBS Group from $88.00 to $89.00. UBS Group currently has a sell rating on the stock.

Palo Alto Networks (NASDAQ:PANW) had its price target boosted by UBS Group from $390.00 to $400.00. UBS Group currently has a neutral rating on the stock.

Pacific Gas & Electric (NYSE:PCG) had its target price raised by JPMorgan Chase & Co. from $17.00 to $19.00. They currently have an overweight rating on the stock.

Royal Bank of Canada (TSE:RY) (NYSE:RY) had its price target increased by Scotiabank from C$312.00 to C$313.00. They currently have a sector outperform rating on the stock.

Septerna (NASDAQ:SEPN) had its target price boosted by JPMorgan Chase & Co. from $48.00 to $51.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) had its price target increased by JPMorgan Chase & Co. from $20.00 to $22.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Toronto-Dominion Bank (TSE:TD) (NYSE:TD) had its price target boosted by Scotiabank from C$187.00 to C$198.00. Scotiabank currently has a sector outperform rating on the stock.

Toronto-Dominion Bank (TSE:TD) (NYSE:TD) had its price target raised by Royal Bank Of Canada from C$173.00 to C$188.00. The firm currently has an outperform rating on the stock.

Universal Technical Institute (NYSE:UTI) had its price target trimmed by Lake Street Capital from $37.00 to $29.00. They currently have a buy rating on the stock.

Woodward (NASDAQ:WWD) had its target price increased by UBS Group from $455.00 to $467.00. They currently have a buy rating on the stock.

XP (NASDAQ:XP) had its target price trimmed by JPMorgan Chase & Co. from $38.00 to $18.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Zai Lab (NASDAQ:ZLAB) had its target price boosted by JPMorgan Chase & Co. from $36.00 to $37.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Receive News & Ratings for ADARx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADARx Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.